Home > Insider Trading > Filing (0001209191-14-021636)

Filing Details

Accession Number:: 0001209191-14-021636
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-03-18 19:22:58
Reporting Period:: 2014-03-14

Filing Date:: 2014-03-18
Accepted Time:: 2014-03-18 19:22:58
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
949858	Oncogenex Pharmaceuticals Inc.	OGXI	In Vitro & In Vivo Diagnostic Substances (2835)	954343413

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1442675	Daniel Scott Cormack	400-1001 W. Broadway Vancouver A1 V6H 4B1	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-03-14	9,376	$0.00	69,614	No	4	M	Direct
Common Stock	Disposition	2014-03-17	4,634	$12.25	64,980	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit (RSU)	Disposition	2014-03-14	4,688	$0.00	4,688	$0.00
Common Stock	Restricted Stock Unit (RSU)	Disposition	2014-03-14	4,688	$0.00	4,688	$0.00
Common Stock	Stock Option (right to buy)	Acquisiton	2014-03-14	50,000	$0.00	50,000	$11.79
Common Stock	Restricted Stock Unit (RSU)	Acquisiton	2014-03-14	25,000	$0.00	25,000	$0.00
Common Stock	Restricted Stock Unit (RSU)	Acquisiton	2014-03-14	40,000	$0.00	40,000	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
9,374	2016-01-31	No	4	M	Direct
14,062	2017-01-31	No	4	M	Direct
50,000	2024-03-14	No	4	A	Direct
25,000	2018-04-13	No	4	A	Direct
40,000	2016-03-31	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	8,092	Indirect	Spouse
Common Stock	49,340	Indirect	By Trycor Investment Trust No. 1

Footnotes

Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.
Represents shares of common stock that have been sold by the issuer to satisfy the tax liability in connection with the settlement of RSUs.
The reporting person and his spouse are the trustees and beneficiaries of the Trycor Investment Trust No. 1.
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement.
Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest on March 12, 2013 and then annually on the later of: (i) each anniversary of January 1, 2012; and (ii) the first day thereafter during which the issuer's trading window is open.
Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2013; and (ii) the first day thereafter during which the issuer's trading window is open.
The options vest in monthly installments over 48 months commencing one month from January 1, 2014.
Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2014; and (ii) the first day thereafter during which the issuer's trading window is open.
Pursuant to the terms of the RSU, 100% of the total shares underlying the RSU vest on the later of (i) the achievement of certain milestones for certain clinical trials, and (ii) the first trading day thereafter on which the issuer's trading window is open, although less than 100% of the total shares may vest upon the achievement of certain, but not all, of the milestones.